glioblastoma
multiform
gbm
frequent
devast
primari
central
nervou
system
tumor
patient
live
beyond
year
postdiagnosi
damag
caus
diseas
treatment
patient
often
leav
physic
cognit
debilit
gener
gbm
appear
short
clinic
histori
discov
imag
use
magnet
reson
imag
mri
diagnosi
valid
patholog
follow
surgic
resect
treatment
respons
diagnosi
tumor
recurr
also
track
mri
numer
problem
encount
monitor
modal
ambigu
interpret
form
pseudoprogress
diagnost
prognost
predict
biomark
would
immens
boon
follow
treatment
scheme
determin
recurr
often
requir
invas
intracrani
biopsi
verifi
imag
data
extracellular
vesicl
ev
stabl
membraneenclos
viruss
particl
releas
either
cell
surfac
endosom
pathway
lead
system
releas
ev
access
biofluid
serumplasma
urin
cerebrospin
fluid
saliva
ev
carri
wide
varieti
protein
nucleic
acid
lipid
metabolit
mani
common
featur
enough
individu
abl
identifi
cell
origin
vesicl
compon
properli
interrog
could
allow
identif
tumorderiv
ev
biofluid
indic
tumor
progress
relaps
treatment
failur
knowledg
would
allow
clinician
continu
treatment
regimen
actual
effect
chang
cours
therapi
fail
review
featur
gbm
ev
term
ev
content
activ
may
lead
use
ev
serial
access
biomark
diagnosi
treatment
respons
neurooncolog
glioblastoma
multiform
gbm
world
health
organ
grade
iv
glioma
common
primari
malign
brain
tumor
unit
state
strike
three
peopl
patient
gbm
face
poor
prognosi
surviv
rate
less
age
group
year
age
virtual
none
aliv
time
roughli
american
diagnos
gbm
year
diseas
claim
live
succumb
year
despit
gross
total
surgic
resect
extern
beam
radiat
treatment
latest
multimod
chemotherapi
therapi
rel
nonspecif
come
signific
cognit
physiopsycholog
cost
patient
brain
organ
toler
much
collater
damag
despit
rel
short
time
cours
diseas
financi
burden
famili
level
stagger
gbm
highli
invas
malign
neoplasm
glial
cell
within
central
nervou
system
carri
poor
prognosi
despit
advanc
surgic
oncolog
modal
neurosurg
resect
gbm
fail
offer
patient
cur
option
even
radiolog
imag
contrast
enhanc
diseas
inadequ
correl
actual
neoplast
diseas
burden
figur
thu
gross
total
resect
use
radiolog
imag
appar
tumor
margin
fail
address
microinfiltr
diseas
beyond
border
radiolog
depict
identifi
upon
histolog
represent
histolog
character
gbm
commonli
show
small
area
central
necrosi
distinct
pseudopalisad
rim
anaplast
glial
cell
hyperplast
hyperperm
vasculatur
differenti
tumor
lowergrad
astrocytoma
figur
c
examin
pseudopalisad
network
neoplast
glial
cell
remark
diseas
heterogen
neoplast
heterogen
observ
gbm
pose
signific
challeng
diseas
treatment
wellknown
oncolog
therapeut
fail
target
entir
diseas
burden
may
actual
select
inher
resist
neoplast
cell
histolog
investig
brain
parenchyma
beyond
locat
radiograph
depict
diseas
often
reveal
signific
microinfiltr
tumor
cell
thought
major
contributor
dismal
prognosi
gbm
inabl
cure
gbm
via
neurosurg
resect
failur
current
therapeut
contribut
urgent
need
gbm
tumor
character
remark
stride
made
recent
molecular
genet
character
gbm
valuabl
initi
understand
detriment
effect
gbm
may
prove
use
stratif
patient
therapeut
respons
andor
clinic
trial
howev
type
tumor
identifi
obvious
evid
tumor
present
access
purpos
serial
monitor
cours
treatment
earli
detect
recurr
tumor
biofluidbas
biomark
essenti
tool
virtual
biofluid
eg
serumplasma
urin
cerebrospin
fluid
breast
milk
semen
colostrum
bronchial
lavag
fluid
ascit
fluid
saliva
synovi
fluid
one
set
common
compon
extracellular
vesicl
consist
exosom
microvesicl
extracellular
vesicl
ev
membraneenclos
viruss
nm
nanovesicl
releas
glioblastoma
extracellular
vesicl
biomark
extracellularli
cell
either
directli
cell
surfac
call
microvesicl
microparticl
ectosom
membran
bleb
via
format
endocyt
rout
fusion
late
endosomemultivesicular
bodi
plasma
membran
exosom
figur
extracellular
releas
deposit
ev
system
circul
fluid
potenti
proxim
distal
effect
vesicl
contain
numer
cellular
constitu
protein
nucleic
acid
lipid
metabolit
common
denomin
term
biogenesi
vesicl
format
cargo
load
constitu
also
suffici
specif
identifi
cell
origin
releas
ev
stabl
protect
constitu
nucleas
proteas
mean
degrad
found
biolog
harsh
extracellular
environ
ev
also
physicochem
properti
enabl
purif
via
standard
procedur
base
featur
ev
appear
verit
repositori
potenti
biomark
health
diseas
clearli
evid
oncolog
well
especi
neurooncolog
need
diagnost
prognost
predic
biomark
urgent
term
biomark
biolog
marker
seem
straightforward
definit
applic
typic
biomark
refer
characterist
object
measur
evalu
indic
normal
biolog
process
pathogen
process
pharmacolog
respons
therapeut
intervent
broad
statement
encompass
aspect
three
recogn
subcategori
biomark
diagnost
marker
identifi
presenc
specif
type
diseas
prognost
marker
use
impli
outcom
independ
therapi
predict
marker
inform
context
particular
treatment
respons
glioma
current
know
noth
truli
use
earlystag
diagnost
biomark
gbm
present
fullblown
tumor
littl
prior
clinic
evid
exist
certain
molecular
featur
gbm
aid
verifi
diagnos
also
prognost
may
predict
studi
ongo
current
line
thought
area
recurr
genet
abnorm
abl
subcategor
gbm
group
defin
classic
mesenychm
proneur
neural
main
featur
design
shown
tabl
gene
express
pattern
genom
alter
associ
gbm
categori
may
eventu
lead
better
therapeut
strategi
design
disturb
correl
patient
proneur
subtyp
show
trend
toward
longer
surviv
compar
patient
three
categori
nonetheless
prolong
surviv
statist
significantli
differ
compar
group
gener
still
less
year
postdiagnosi
import
realiz
molecular
signatur
gbm
base
analys
actual
tumor
specimen
biopsi
thu
use
molecul
ongo
monitor
patient
progress
respons
therapi
may
limit
suggest
biofluidbas
biomark
like
far
practic
benefit
circul
biomark
may
serial
collect
essenti
therapeut
assess
usual
minim
invas
natur
collect
compar
substanti
intracrani
intervent
surgeri
biopsi
also
attract
mention
gbm
present
acut
rel
clear
indic
oncom
pathogenesi
redzic
et
al
usual
headach
seizur
intracrani
pressur
vision
hear
issu
even
person
chang
make
window
earli
diseas
screen
almost
nonexist
imag
techniqu
magnet
reson
imag
mri
magnet
reson
spectroscopi
mr
standard
brain
tumor
diagnost
clearli
valuabl
limit
use
tumor
suspect
due
aforement
symptom
also
techniqu
extrem
expens
entir
brain
tumor
afflict
imag
modal
gener
offer
littl
histolog
prognost
inform
without
employ
special
technolog
variou
form
positron
emiss
tomagraphi
vessel
architectur
imag
stimul
raman
scatter
beyond
accept
diagnos
made
intraor
postop
patholog
offer
prognost
evalu
use
immunohistochemistri
genet
techniqu
obvious
test
requir
tumor
access
surgeri
biopsi
intracrani
invas
procedur
especi
true
recurr
tumor
occur
nearli
patient
highgrad
glioma
imag
distinct
remnant
tumor
regrowth
postradi
necrosi
difficult
pseudoprogress
radiograph
indic
usual
gadolinium
enhanc
appear
progress
grow
tumor
follow
radiat
later
resolv
devolv
radiat
necrosi
anoth
common
problem
tumor
diagnosticbiomark
capabl
access
compart
bloodsera
urin
saliva
would
major
advanc
neurooncolog
especi
sinc
seem
circul
exfoli
brain
tumor
cell
cerebr
spinal
fluid
offer
mix
result
thu
biomark
effort
gbm
gear
toward
determin
recurr
diseas
either
context
standard
care
treatment
clinic
trial
set
emphasi
clinicallevel
assess
protein
previous
identifi
put
gbm
biomark
blood
may
close
associ
gbm
treatment
marker
neurotrauma
rather
unequivoc
relat
tumor
protein
includ
glial
fibrillari
acid
protein
gfap
vascular
endotheli
growth
factor
vegf
epiderm
growth
factor
receptor
egfr
basic
fibroblast
growth
factor
bfgf
protein
matrix
metalloproteinas
factor
known
secret
tumor
immun
cell
follow
encount
gbm
includ
transform
growth
factor
beta
famili
member
well
interleukin
far
clinic
valid
serumborn
molecul
glioma
biomark
research
ongo
littl
mention
circul
lipid
speci
put
biomark
gbm
among
glioblastoma
extracellular
vesicl
biomark
lipid
describ
brainspecif
identifi
system
blood
circul
howev
hydroxycholesterol
seem
appear
high
level
serum
follow
sever
central
nervou
system
cn
trauma
necessarili
respons
brain
tumor
level
free
nucleic
acid
circul
low
difficult
detect
due
lack
protect
nucleas
present
circul
system
howev
potenti
biomark
candid
propos
circul
nucleic
acid
content
serum
plasma
gbm
patient
consist
deoxyribonucl
acid
dna
ribonucl
acid
rna
speci
summar
review
holdhoff
et
al
briefli
potenti
circul
tumor
dna
biomark
includ
methyl
promot
region
methyltransferas
mgmt
cyclindepend
kinas
inhibitor
deathassoci
protein
kinas
dapk
ra
associ
ralgd
domain
famili
member
other
also
shown
methyl
promot
region
mgmt
phosphatas
tensin
homolog
pten
howev
detect
rate
epigenet
chang
low
serum
sampl
detect
case
pten
compar
astrocyt
tumor
sampl
addit
author
analyz
loss
heterozygos
loh
chromosom
oligodendrogli
tumor
report
higher
percentag
loh
tumor
tissu
compar
serum
sampl
differ
rna
speci
also
detect
circul
egfrviii
messag
detect
platelet
isol
glioma
patient
circul
tumor
microrna
mirna
also
detect
blood
gbm
patient
studi
mirna
mirna
shown
upregul
blood
gbm
patient
cohort
studi
rel
small
less
patient
analysi
molecul
perform
higher
number
patient
provid
evid
use
molecul
biomark
addit
unclear
small
mirna
present
serum
without
form
proteinac
membraneenclos
protect
ev
may
provid
protect
term
exosom
use
describ
exfoli
microvesicl
rat
glioma
line
year
ago
vesicl
size
nm
would
describ
today
microvesicl
origin
appear
cell
surfac
rather
endosom
earlier
studi
unclear
whether
control
use
fetal
calf
serum
supplement
cell
cultur
medium
known
fetal
bovin
sera
frequent
use
cell
cultur
contain
extracellular
vesicl
vesicl
may
clear
centrifug
ie
g
prior
inclus
sera
cultur
medium
may
first
describ
exosom
brain
tumor
cell
line
human
murin
sourc
studi
soon
follow
import
public
alnedawi
et
al
skog
et
al
former
demonstr
presenc
gliomaspecif
mutant
egfr
variant
iii
egfrviii
ev
cell
line
transfect
mutant
construct
ev
sera
mice
grow
egfrviiiexpress
tumor
incub
glioma
cell
express
mutant
receptor
ev
cell
express
show
transfer
egfrviii
nonexpress
cell
concomit
activ
tumorpromot
signal
pathway
associ
egfrviii
signal
extracellular
signalregul
kinas
erk
protein
kinas
b
akt
phosphoryl
vegf
releas
latter
paper
demonstr
presenc
mrna
mirna
sera
patient
gbm
may
diagnost
util
major
advantag
nucleic
acid
technolog
regard
ev
standard
preparationhandl
condit
one
abil
amplifi
signal
small
amount
start
materi
possibl
biolog
eg
protein
lipid
paper
also
show
differenti
distribut
specif
messeng
rna
ev
compar
rel
amount
cell
origin
model
mrna
could
passag
cell
cell
ev
result
translat
mrna
protein
recipi
cell
among
mrna
found
least
patient
serum
ev
encod
egfrviii
tumorspecif
marker
final
ev
angiogenicpromot
activ
human
brain
microvascular
endotheli
cell
group
later
show
egfrviii
appear
surfac
exosom
egfrviiiexpress
cell
along
heat
shock
protein
hsp
egfrviii
protein
could
identifi
ev
sera
patient
gbm
howev
egfr
seem
present
sera
ev
patient
healthi
donor
exosom
murin
brain
tumor
line
serv
potent
anticanc
vaccin
prophylact
set
larg
redzic
et
al
ineffectu
stringent
therapeut
set
suggest
immun
respons
tumor
exosom
may
strongli
contextdepend
also
perform
first
proteom
survey
brain
tumor
exosom
studi
identifi
distinct
protein
includ
endogen
murin
retrovir
gag
polyprotein
protein
indic
retroviru
known
involv
progress
murin
tumor
subvers
immun
surveil
paper
note
immun
dichotomi
brain
tumor
exosom
demonstr
presenc
put
tumor
antigen
well
number
immunosuppress
entiti
articl
interest
shown
variou
brain
tumor
cell
ev
gbm
oligodendroglioma
cell
medulloblastoma
cell
activ
impact
recipi
cell
rang
transform
cell
induct
apoptosi
along
growth
promot
migratorydriv
activ
paper
show
immun
dichotomi
medulloblastoma
exosom
immunosuppress
immunostimulatori
function
identifi
almost
protein
proteom
analys
furthermor
studi
exosomesev
isloat
hypox
gbm
cell
enhanc
gbm
bioactiv
induc
epitheli
cell
secret
tumorpromot
factor
result
increas
tumor
growth
migrat
vascular
angiogenesi
involv
paracrin
signal
via
tissu
factor
associ
ev
thu
exosomesev
serv
transfer
mechan
tumor
surviv
progress
curious
coagulopathi
part
comorbid
associ
brain
tumor
tissu
factor
like
play
signific
part
presenc
ev
well
known
role
tissu
factor
context
ev
remain
unclear
may
repres
area
therapeut
intervent
expand
extrem
interest
public
describ
role
ev
biolog
gbm
attempt
find
clear
utiliz
biomark
earli
stage
field
face
lack
outcom
plagu
cancer
biomark
field
year
ie
larg
number
put
biomark
input
approv
entiti
output
develop
use
robust
clinic
viabl
biomark
follow
complex
multiphas
pathway
harsh
gonogo
decis
fraught
difficulti
involv
biolog
bioinformat
current
plu
develop
current
unforeseen
biotechnolog
howev
biomark
tie
clinic
drug
develop
platform
form
companion
diagnost
multiplex
system
may
necessari
valid
drug
efficaci
ev
like
play
vital
role
reservoir
multipl
type
biolog
materi
suitabl
biomark
assay
allud
previous
ev
contain
protein
nucleic
acid
lipid
metabolit
reflect
cell
origin
individu
multipl
entiti
amongst
biomateri
may
prove
identifi
cancer
cell
host
ev
present
purifi
essenti
routin
obtain
biofluid
distinct
advantag
scenario
ev
bundl
multipl
potenti
biomark
one
packag
thu
multiplex
assay
evalu
one
biomateri
eg
rna
protein
could
theoret
perform
sampl
concept
liquid
biopsi
often
appli
circul
tumor
cell
recent
circul
cellfre
cf
dna
number
circul
tumor
cell
often
low
even
nonexist
case
patient
gbm
cfdna
larg
nontumor
origin
ev
overcom
barrier
liquid
biopsi
ev
known
occur
elev
quantiti
blood
cancer
patient
protein
nucleic
acid
content
tumorspecif
background
explor
known
may
possibl
concern
use
ev
biomark
gbm
perhap
best
known
specif
protein
marker
gbm
egfrviii
identifi
cell
line
patient
serum
ev
tumorspecif
mutat
also
found
sever
cancer
type
overexpress
egfr
delet
amino
acid
extracellular
domain
result
truncat
receptor
clear
ligand
nonetheless
signal
constitut
discrep
concern
frequenc
mutant
protein
gbm
patient
sampl
perhap
result
differ
techniqu
reagent
estim
rang
thu
egfrviii
seem
excel
put
biomark
diagnost
perspect
loss
express
may
predict
biomark
protein
directli
target
howev
like
evalu
protein
statu
would
direct
assess
access
antibodi
reagent
limit
result
use
nucleic
acid
techniqu
detect
remain
concern
lack
correl
polymeras
chain
reaction
pcr
base
detect
egfrviii
actual
protein
express
level
specif
sensit
issu
may
depend
techniqu
employ
gene
amplif
egfr
common
gbm
overexpress
protein
egfrviii
express
subset
egframplifi
tumor
other
identifi
egfr
ev
gbm
cell
patient
sera
also
appear
ev
healthi
donor
nontumor
cell
line
beg
question
specif
howev
may
valuabl
biomark
tool
part
multiparamet
screen
assay
limit
studi
also
identifi
avian
erythroblast
leukemia
viral
oncogen
homolog
human
epiderm
growth
factor
receptor
rel
specif
marker
ev
patient
medulloblastoma
perhap
gbm
probe
express
protein
may
also
use
biomark
unclear
whether
incorpor
ev
healthi
donor
much
larger
sampl
size
necessari
establish
correl
protein
list
put
circul
protein
biomark
gbm
found
ev
mrna
identifi
identifi
gfap
medulloblastoma
also
identifi
healthi
donor
human
plasma
ev
suggest
may
tumorspecif
vegfa
protein
identifi
human
gbm
cell
line
ev
antibodi
array
far
appear
normal
cell
ev
carri
obvious
tumorspecif
marker
li
et
al
identifi
protein
proteom
analysi
cell
linederiv
ev
one
myoferlin
previous
identifi
ev
group
found
bfgf
also
call
medulloblastoma
ev
suggest
may
tumor
marker
tumorspecif
true
mrna
found
gbm
ev
protein
present
activ
ovarian
cancer
ev
mmp
extracellular
proteas
play
import
role
modifi
tumor
microenviron
angiogenesi
migrat
invas
implic
ev
major
player
import
function
gbm
leav
host
profoundli
immunosuppress
effect
often
link
cytokin
produc
immun
system
cell
identifi
ev
compon
cancer
normal
cell
type
may
question
regard
normal
background
amount
cytokin
ev
identifi
come
mesenchym
stem
cell
ev
activ
ev
thymu
cell
origin
may
drive
regulatori
cell
phenotyp
curious
saw
appear
latent
form
serum
ev
patient
gbm
sinc
activ
serum
halflif
minut
transport
blood
may
reli
ev
tumorspecif
mutat
identifi
brain
tumor
isocitr
dehydrogenas
mutat
far
preval
lowergrad
glioma
secondari
glioma
high
grade
gbm
identifi
proteom
medulloblastoma
ev
peptid
sequenc
coverag
includ
potenti
mutat
region
howev
use
antibodi
specif
mutant
protein
shao
et
al
includ
enzym
part
fourprotein
gbm
molecular
signatur
interrog
gbm
cell
line
patient
sera
ev
part
micro
nuclear
magnet
reson
micronmr
devic
studi
indic
molecular
signatur
coupl
extrem
sensit
instrument
could
accur
type
respond
vs
nonrespond
anim
model
patient
receiv
therapi
gbm
strongli
suggest
effect
biomark
may
come
packag
ev
utiliz
panel
rather
individu
entiti
also
suggest
despit
nanoscal
ev
microfabr
devic
capabl
interrog
vesicl
clinic
applic
truli
possibl
rel
littl
known
lipid
compon
ev
learn
time
nonetheless
almost
noth
report
lipid
content
gbm
ev
serum
associ
cn
trauma
brain
tumor
still
unclear
whether
method
extract
identif
would
encompass
signific
popul
extracellular
vesicl
cholesterol
one
highli
enrich
lipid
extracellular
vesicl
thu
may
cnsenrich
specif
lipid
marker
ev
cn
tumor
discoveri
pend
nucleic
acid
content
ev
quit
divers
skog
et
al
first
report
mrna
mirna
content
gbm
ev
balaj
et
al
found
ev
differ
type
cn
tumor
contain
singlestrand
dna
complementari
c
dna
genom
dna
well
retrotranspos
element
redzic
et
al
rna
packag
glioma
ev
mirna
may
use
sourc
biomark
potenti
gbm
given
differ
mirna
signatur
healthi
subject
gbm
patient
although
nucleic
acid
content
ev
divers
potenti
biomark
suggest
date
protein
content
gbmderiv
ev
egfrviii
mrna
also
one
specif
wellknown
marker
detect
ev
work
skog
et
al
purifi
ev
serum
gbm
patient
detect
egfrviii
mrna
sampl
test
use
pcrbase
method
percentag
egfrviii
mrna
compar
total
rna
ev
consist
percentag
gbm
patient
posit
particular
mutat
ie
gbm
patient
egfrviii
mutat
detect
egfrviii
rna
glioma
ev
also
report
nilsson
et
al
found
ev
use
transfer
messag
recipi
cell
work
chen
et
al
promis
potenti
use
detect
mutat
csf
biomark
especi
consid
sensit
techniqu
author
use
sensit
pcr
method
detect
quantifi
wildtyp
mutant
transcript
ev
isol
csf
glioma
patient
found
higher
level
mutant
csf
patient
glioma
compar
healthi
control
sensit
techniqu
evid
consid
mutant
rel
rare
patient
gbm
howev
sourc
materi
csf
prime
candid
serial
evalu
biomark
statu
mention
li
et
al
detect
sever
differ
type
rna
glioma
ev
particular
interest
find
cell
line
deriv
ev
detect
high
level
consist
skog
et
al
find
complement
result
skog
et
al
also
show
high
express
serum
ev
patient
gbm
result
group
consist
report
highli
overexpress
glioma
tissu
suggest
clear
potenti
biomark
gbm
particularli
context
put
marker
point
specif
gbm
also
found
ev
healthi
donor
context
commun
like
import
determin
util
mirna
biomark
sophist
sensit
pcr
methodolog
becom
robust
wide
usabl
diagnost
set
conceiv
detect
highli
abund
gbmspecif
mirna
biofluid
ev
possibl
may
provid
addit
biomark
candid
surfac
ev
contain
great
deal
inform
rel
size
tini
vesicl
consid
rel
limit
intern
volum
variou
aspect
ev
surfac
may
reveal
much
abil
differenti
repres
presenc
tumor
vs
normal
cell
chang
tumor
cell
due
treatment
surfac
cancer
cell
often
differenti
glycosyl
compar
normal
cell
counterpart
thu
suggest
tumor
glycom
may
distinguish
tumor
cell
normal
cell
technolog
carbohydr
analys
progress
includ
better
separ
mass
spectrometri
identif
well
microarraystyl
highthroughput
method
glycosyl
surfac
ev
either
form
glycoprotein
glycolipid
surfacebound
carbohydr
ripe
type
probe
recent
batista
et
al
util
lectin
array
studi
glycom
ev
harvest
sever
differ
sourc
show
differ
cell
surfac
glycom
result
ev
glycom
tend
conserv
although
distinguish
featur
gross
glycom
composit
urinari
exosom
surfac
glycosyl
also
proven
distinguish
ev
healthi
donor
vs
polycyst
kidney
diseas
suggest
surfac
phenomena
may
harbor
carbohydr
biomark
recent
report
particular
antibodi
recogn
brain
tumorspecif
gangliosid
andor
would
bind
glioma
exosom
demonstr
antigen
could
present
circul
ev
biomark
rel
unexplor
area
ev
biolog
may
hold
great
promis
mean
identifi
pathologyrel
circul
ev
ev
surfac
proteom
like
contain
protein
particular
glycoprotein
reflect
cancer
state
gbm
stem
cell
use
profil
cell
surfac
glycoprotein
whose
express
upregul
neurospher
stem
cell
compar
classic
longterm
adher
cultur
receptortyp
tyrosin
protein
phosphatas
phosphacan
glioblastoma
extracellular
vesicl
biomark
tenascinc
chondroitin
sulfat
proteoglycan
podocalyxinlik
protein
cluster
differenti
cd
upregul
compar
downregul
glycoprotein
tenascin
c
identifi
ev
antibodi
specif
recogn
brain
tumor
tenascin
c
well
potenti
therapeut
antibodi
thu
stem
cell
portion
gbm
may
surfac
marker
could
releas
ev
due
associ
stem
cell
tumor
therapeut
resist
may
valuabl
marker
harbing
impend
recurr
mention
group
identifi
egfrviii
glioma
cell
ev
surfac
along
hsp
later
show
medulloblastoma
ev
surfac
presenc
hsp
brain
tumor
ev
surfac
fit
demonstr
hsp
chaperon
surfac
varieti
brain
tumor
cell
protein
typic
regard
intracellularli
local
data
suggest
locat
may
relat
biomark
statu
tumor
alter
standard
local
protein
newer
technolog
nanoparticl
track
analysi
nta
fluoresc
usual
antibodi
stain
allow
specif
quantif
label
vesicl
within
overal
popul
vesicl
present
thu
allow
detect
enumer
put
tumor
patholog
ev
mix
field
vesicl
eg
serum
urin
anoth
use
antibodi
detect
surfac
intern
ev
content
mention
previous
use
microfluid
nmr
chip
gbm
ev
label
lyse
intern
materi
label
target
magnet
nanoparticl
fourprotein
signatur
egfr
egfrviii
podoplanin
pdpn
mutant
render
ev
superparamagnet
yield
faster
proton
decay
rate
enhanc
nmr
signal
none
marker
individu
high
sensit
overal
good
specif
combin
four
marker
result
high
sensit
specif
abil
quantifi
ev
sever
log
better
current
technolog
major
messag
multipl
biomark
may
abl
overcom
limit
one
one
interest
host
respons
tumor
ev
antibodi
respons
presum
surfac
antigen
shown
model
known
antigen
load
ev
also
shown
hightit
murin
respons
natur
occur
brain
tumor
antigen
respons
occur
quickli
absenc
adjuv
convers
tumor
antigen
eg
surfac
circul
tumorderiv
ev
capac
bind
effect
titrat
therapeut
antibodi
trastuzumab
potenti
reduc
effect
drug
appear
natur
antibodi
recogn
reticulocyt
ev
potenti
involv
elimin
apoptot
bodi
shown
circul
ev
sera
patient
gbm
carri
substanti
amount
bound
antibodi
antibodi
may
elut
ev
least
fraction
antibodi
recogn
tumor
antigen
gbm
cell
line
western
blot
rais
possibl
antibodi
circul
tumor
ev
may
abl
reveal
presenc
tumor
antigen
may
produc
signatur
highdens
protein
peptid
array
alert
tumor
presenc
predict
perspect
one
issu
would
lack
knowledg
clearanc
halfliv
antibodi
may
valu
initi
diagnost
perspect
one
consid
concept
particular
molecular
entiti
ev
may
difficult
identifi
ascertain
recogniz
differ
tumor
normal
cell
type
howev
collect
materi
may
endem
measur
activ
could
distinguish
patholog
normal
state
connect
tumorigen
measur
readout
ev
may
abl
induc
respons
model
cell
type
could
reveal
presenc
tumor
perhap
even
situat
aggress
measur
tumor
follow
possibl
area
assay
develop
biologicmetabol
enzym
repres
protein
found
brain
tumor
exosom
glycolyt
enzym
among
top
ten
protein
identifi
ev
ronquist
et
al
recent
demonstr
prostasom
ev
releas
prostat
gland
semin
fluid
function
gener
adenosin
triphosph
atp
substrat
glucos
fructos
indic
ev
intrins
metabol
capac
recent
show
ev
sera
patient
gbm
possess
tumorassoci
enzym
pyruv
kinas
necessari
warburg
effect
addit
ev
gbm
cell
increas
express
variou
metabol
enzym
recipi
cell
one
potenti
effect
increas
enzym
quantiti
could
increas
measur
previous
demonstr
medulloblastoma
cell
migrat
toward
ev
use
attract
boyden
chamber
transwel
migrat
assay
proven
true
ev
tumor
type
like
biolog
diagnost
signific
certain
element
ev
activ
eg
extracellular
proteolyt
activ
may
use
measur
output
appropri
assay
ev
known
transport
phosphoprotein
put
signal
potenti
gbm
ev
alter
signal
pathway
within
recipi
cell
similar
assay
unpublish
data
show
ev
stress
gbm
cell
ie
induc
undergo
unfold
protein
respons
drive
extens
chang
receptor
tyrosin
kinas
signal
pathway
recipi
gbm
cell
ev
unstress
cell
shown
one
could
imagin
standard
cell
line
assay
ev
patient
bodi
fluid
incub
model
cell
line
lyse
assay
specif
ie
limit
chang
phosphoprotein
statu
indic
tumor
evdriven
phenotyp
alter
conceiv
ev
could
lyse
expos
phosphoantibodi
array
might
reveal
presenc
high
level
tumorassoci
phosphoprotein
ev
protein
posttransl
modif
may
indic
tumor
presenc
may
includ
glycosyl
see
ubiquitin
citrullin
acyl
lipid
modif
like
scratch
surfac
understand
posttransl
modif
impact
cargo
load
ev
potenti
downstream
biolog
signific
ev
show
great
promis
reservoir
biomark
patient
glioblastoma
presenc
ev
everi
biofluid
allow
theoret
easi
access
minim
noninvas
fashion
assort
biomolecul
sure
provid
signatur
presenc
diseas
chang
diseas
state
case
compon
signatur
truli
tumorspecif
case
gbm
perhap
egfrviii
idh
mutant
tumorrestrict
thu
may
need
quantifi
potenti
combin
biomark
possibl
locat
ev
distinguish
signatur
distinct
normal
tissu
ev
signatur
may
readabl
translat
via
bioassay
rather
direct
identif
letter
word
signatur
great
need
biomark
develop
neurooncolog
sinc
current
imag
system
often
fail
provid
adequ
inform
concern
recurr
tumor
growth
current
biolog
statu
either
primari
recurr
tumor
pauciti
inform
tend
drive
fairli
uniform
treatment
regimen
everi
patient
thu
fail
account
person
approach
monitor
diseas
individu
respons
therapi
may
circul
fat
ball
provid
window
presenc
statu
tumor
give
us
therapeut
edg
treatment
devast
diseas
submit
manuscript
wwwdovepresscom
submit
manuscript
http
wwwdovepresscompharmacogenomicsandpersonalizedmedicinejourn
pharmacogenom
person
medicin
intern
peerreview
open
access
journal
character
influenc
genotyp
pharmacolog
lead
develop
person
treatment
program
individu
drug
select
improv
safeti
efficaci
sustain
journal
index
american
chemic
societi
chemic
abstract
servic
ca
manuscript
manag
system
complet
onlin
includ
quick
fair
peerreview
system
easi
use
visit
http
wwwdovepress
comtestimonialsphp
read
real
quot
publish
author
